Record Number of Total Artificial Heart Abstracts to be Presented by 20+ SynCardia Certified Centers at ISHLT

Topics Include Home Discharge Using the Freedom® Portable Driver and Use of the Total Artificial Heart for Adolescents, Congenital Patients and Destination Therapy

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
SynCardia, Total Artificial Heart, artificial heart, donor hear, heart failure, heart transplant

The 50cc SynCardia Total Artificial Heart is designed for use in patients of smaller stature, including women and adolescents. It has been designated as a Humanitarian Use Device (HUD) by the FDA for destination therapy and pediatric bridge to transplant. Prior to clinical use, a Humanitarian Device Exemption (HDE) application for each indication must be approved by the FDA.

Transplant programs throughout the world are making the SynCardia Total Artificial Heart the new standard of care for end-stage biventricular heart failure.

Tucson, Ariz. (PRWEB) April 11, 2013

SynCardia Systems, Inc. (http://www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that more than 20 SynCardia Certified Centers representing four countries and more than 70 authors will present a record number of abstracts discussing the SynCardia temporary Total Artificial Heart at the annual meeting of the International Society for Heart & Lung Transplantation (ISHLT) being held April 24-27 in Montreal, Canada.

“Transplant programs throughout the world are making the SynCardia Total Artificial Heart the new standard of care for end-stage biventricular heart failure,” said Michael Garippa, SynCardia Chairman/CEO/President. “SynCardia Certified Centers have amassed a wealth of knowledge and experience in using the Total Artificial Heart, and sharing this information with the international transplant community is critical to creating and sustaining good patient outcomes worldwide.”

Key ISHLT presentations on the SynCardia Total Artificial Heart, ordered by date and time, include:

Wednesday, April 24, 2013

•3:25 PM: Total Artificial Heart
Francisco A. Arabia, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA
SYMPOSIUM 13: Machines vs. Medications for Biventricular Failure (2:15 PM-4:15 PM)
Room: 517CD

Thursday, April 25, 2013

•5:30 PM: Characteristics and Survival of Patients with the Total Artificial Heart Implanted for Indications Other Than Biventricular Failure
Poster Session 2: Mechanical Circulatory Support (10 AM-6:30 PM)
Room: 516

•5:30 PM: Clinical Outcomes for INTERMACS Profile 1 Patient Implanted with the Total Artificial Heart
Poster Session 2: Mechanical Circulatory Support (10 AM-6:30 PM)
Room: 516

Friday, April 26, 2013

•5:15 PM: Worldwide Use of SynCardia Total Artificial Heart in Adolescents: A 25-Year Experience
Concurrent Session 35: PEDS 2: Mechanical Circulatory Support in Children (4-5:30 PM)
Room: 513ABC

•5:30 PM: Home Discharge and Out-of-Hospital Follow-Up of Total Artificial Heart Patients Supported by a Portable Driver
Poster Session 3: Mechanical Circulatory Support (9 AM-6:30 PM)
Room: 516

•6:05 PM: Long Term Results with Total Artificial Heart: Is It Prime Time for Destination Therapy?
Mini Oral Session 7: Mechanical Circulatory Support II (5:30-6:30 PM)
Room: 513DEF

Saturday, April 27, 2013

•1:03 PM: The Worldwide Use of SynCardia Total Artificial Heart in Patients with Congenital Heart Disease
Concurrent Session 41: MCS 10: Outcomes Potpourri (12:15-1:30 PM)
Room: 511

•1:15 PM: Artificial Heart Patients Discharged Home with a Portable Pneumatic Driver –
The Pivotal US Clinical Trial Experience
Concurrent Session 44: MCS 11: Translational Science and New Devices (12:15-1:30 PM)
Room: 513ABC

In addition, on Wednesday, April 24, SynCardia will be hosting a panel discussion titled, “Moving Forward: The Freedom Experience, the Bi-Leaflet Valve TAH, and End-Organ Recovery.” Medical professionals interested in attending should contact Vivian Wessel at vwessel(at)syncardia(dot)com.

###

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among “America’s Most Promising Companies”

In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.


Contact